NewsRx

Search our medical news database

Cobalis Corp.

PreHistin to be granted European Union patent

Published in Pharma Law Weekly, November 29th, 2005

Cobalis Corp. (CLSC) announced that following an oral presentation to the European Patent Office in Munich, Germany, a panel of three patent examiners accepted Cobalis' claims for PreHistin as a unique treatment for allergies and other atopic diseases.

The patent "Cyanocobalamin Treatment in Allergic Disease," European Patent EP1128835, grants Cobalis extensive patent protection paving the way for marketing PreHistin throughout the European Union where an estimated 80 million people suffer from seasonal and perennial allergies, as well as a host of other atopic diseases such as atopic asthma, atopic migraine and dermatitis.

PreHistin is a sublingual...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook